Safety and efficacy of hepatic artery embolization in heavily treated patients with intrahepatic cholangiocarcinoma: Analysis of clinicopathological and radiographic parameters associated with better overall survival Journal Article
| Authors: | Velayati, S.; Elsakka, A.; Zhao, K.; Erinjeri, J. P.; Marinelli, B.; Soliman, M.; Chevallier, O.; Ziv, E.; Brody, L. A.; Sofocleous, C. T.; Solomon, S. B.; Harding, J. J.; Abou-Alfa, G. K.; D'Angelica, M. I.; Wei, A. C.; Kingham, P. T.; Jarnagin, W. R.; Yarmohammadi, H. |
| Article Title: | Safety and efficacy of hepatic artery embolization in heavily treated patients with intrahepatic cholangiocarcinoma: Analysis of clinicopathological and radiographic parameters associated with better overall survival |
| Abstract: | The safety and efficacy of hepatic artery embolization (HAE) in treating intrahepatic cholangiocarcinoma (IHC) was evaluated. Initial treatment response, local tumor progression-free survival (L-PFS), and overall survival (OS) were evaluated in 34 IHC patients treated with HAE. A univariate survival analysis and a multivariate Cox proportional hazard analysis to identify independent factors were carried out. Objective response (OR) at 1-month was 79.4%. Median OS and L-PFS from the time of HAE was 13 (CI = 95%, 7.4–18.5) and 4 months (CI = 95%, 2.09–5.9), respectively. Tumor burden < 25% and increased tumor vascularity on preprocedure imaging and surgical resection prior to embolization were associated with longer OS (p < 0.05). Multivariate logistic regression analysis demonstrated that tumor burden < 25% and hypervascular tumors were independent risk factors. Mean post-HAE hospital stay was 4 days. Grade 3 complication rate was 8.5%. In heavily treated patients with IHC, after exhausting all chemotherapy and other locoregional options, HAE as a rescue treatment option appeared to be safe with a mean OS of 13 months. Tumor burden < 25%, increased target tumor vascularity on pre-procedure imaging, and OR on 1 month follow-up images were associated with better OS. Further studies with a control group are required to confirm the effectiveness of HAE in IHC. |
| Journal Title: | Current Oncology |
| Volume: | 30 |
| Issue: | 10 |
| ISSN: | 1198-0052 |
| Publisher: | Multimed Inc |
| Date Published: | 2023-10-01 |
| Start Page: | 9181 |
| End Page: | 9191 |
| Language: | English |
| DOI: | 10.3390/curroncol30100663 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PMCID: | PMC10605490 |
| PUBMED: | 37887563 |
| DOI/URL: | |
| Notes: | Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work